Possis Medical
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application is filed with FDA covering the AngioJet Rheolytic thrombectomy system to remove blood clots from coronary blood vessels. The Minneapolis firm has requested expedited review for the submission, which includes results of a 349-patient randomized trial comparing AngioJet to intracoronary infusion of urokinase in patients with demonstrated clot in native coronary arteries and saphenous vein bypass grafts. The trial showed that AngioJet patients "had significantly better outcomes...for procedure success and device success," Possis claims. The product currently is approved for treatment of dialysis access graft thrombosis
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.